A report claims that despite significant interest in implementing continuous bioprocesses, fully continuous systems are five to 10 years away from widespread adoption.
Abbott’s glucose sensing technology and a tubeless insulin delivery system developed by Insulet are set to create a personalized diabetes management solution.
In its latest deal, BIA Separations brings to market an elution method developed by the University of Zagreb, which helps preserve viruses’ integrity, infectivity, and potency.
Under an agreement with Zumutor, Catalent Biologics initiates clinical manufacture of the latter’s lead candidate targeting solid tumors, ahead of FDA filing.
Year-on-year, the number of trials for advanced therapeutics has doubled, meaning that the UK now represents 12% of all global clinical trials in the area.
Almirall enters drug discovery agreement with WuXi Biologics, gaining access to the WuXiBody platform to develop antibodies for the treatment of dermatological diseases.